Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | 2026-10-08 08:46:28 | 34.41 | -0.69 | -1.95 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFTX | 0001813814 | Definium Therapeutics, Inc. | CA60255C8850 | 549300QY8KN1O6RPFJ13 | — | Nasdaq | 2833 | Medicinal Chemicals & Botanical Products | 1231 | A1 | ONE WORLD TRADE CENTER | NEW YORK | NY | 10007 | UNITED STATES | US | 212-220-6633 | ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 | ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 | Mind Medicine (MindMed) Inc. | Biotechnology | 2019 | Robert Barrow | 57 | https://definiumtx.com/ | 487,700,000 | 134,365,950 | 134,366,950 | Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. | 2026-10-01 19:14:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 487,700,000 | -27,700,000 | -5.3745 | 99,698,129 | 24,329,770 | 32.2811 |
| 2024 | 515,400,000 | 375,400,000 | 268.1429 | 75,368,359 | 34,034,052 | 82.3385 |
| 2023 | 140,000,000 | -132,000,000 | -48.5294 | 41,334,307 | 3,270,922 | 8.5934 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Daniel Karlin | Chief Medical Officer | 2025 | 510,000 | 0 | 3,262,525 | 214,200 | 14,533 | 4,001,258 |
| Brandi L. Roberts | Chief Financial Officer | 2025 | 288,750 | 0 | 1,815,000 | 121,322 | 401 | 5,116,362 |
| Robert Barrow | Chief Executive Officer | 2025 | 655,000 | 0 | 11,719,750 | 378,263 | 14,429 | 12,767,442 |
| Robert Barrow | Chief Executive Officer | 2024 | 623,500 | 0 | 0 | 359,216 | 14,294 | 2,669,010 |
| Mark Sullivan | Chief Legal Officer | 2024 | 439,750 | 0 | 0 | 184,288 | 14,569 | 1,161,107 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 105 |
| 2024 | 74 |
| 2023 | 57 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 0 | 0 | 0 |
| Research And Development Expenses | 117,665,000 | 65,297,000 | 52,124,000 |
| General And Administrative Expenses | 48,644,000 | 38,619,000 | 41,742,000 |
| Operating Expenses | 166,309,000 | 103,916,000 | 93,866,000 |
| Operating Income | -166,309,000 | -103,916,000 | -93,866,000 |
| Net Income | -183,793,000 | -108,679,000 | -95,732,000 |
| Earnings Per Share Basic | -2.06 | -1.54 | -2.44 |
| Earnings Per Share Diluted | -2.06 | -1.54 | -2.44 |
| Weighted Average Shares Outstanding Basic | 89,327,608 | 70,461,067 | 39,157,420 |
| Weighted Average Shares Outstanding Diluted | 89,327,608 | 70,461,067 | 39,157,420 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 257,837,000 | 273,741,000 | 99,704,000 |
| Marketable Securities Current | 153,756,000 | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 7,727,000 | 7,879,000 | 4,168,000 |
| Total Assets Current | 419,320,000 | 281,620,000 | 103,872,000 |
| Marketable Securities Non Current | 17,866,000 | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 862,000 | 613,000 | 224,000 |
| Total Assets Non Current | 20,780,000 | 20,531,000 | 20,669,000 |
| Total Assets | 440,100,000 | 302,151,000 | 124,541,000 |
| Accounts Payable | 5,347,000 | 2,010,000 | 4,136,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 20,446,000 | 12,829,000 | 11,634,000 |
| Total Liabilities Current | 66,698,000 | 38,849,000 | 32,246,000 |
| Long Term Debt | 40,579,000 | 21,854,000 | 14,129,000 |
| Other Liabilities Non Current | 496,000 | — | 32,000 |
| Total Liabilities Non Current | 41,075,000 | 21,854,000 | 14,161,000 |
| Total Liabilities | 107,773,000 | 60,703,000 | 46,407,000 |
| Common Stock | — | 0 | — |
| Retained Earnings | -582,672,000 | -398,879,000 | -290,200,000 |
| Accumulated Other Comprehensive Income | 1,085,000 | 819,000 | 343,000 |
| Total Shareholders Equity | 332,327,000 | 241,448,000 | 78,134,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | — | — | — |
| Share Based Compensation Expense | — | — | — |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -30,000 | -48,000 | -51,000 |
| Change In Accounts Payable | 3,337,000 | -2,126,000 | 2,025,000 |
| Change In Other Liabilities | 5,958,000 | 3,103,000 | 5,318,000 |
| Cash From Operating Activities | -131,560,000 | -79,129,000 | -64,365,000 |
| Purchases Of Marketable Securities | 268,356,000 | — | — |
| Sales Of Marketable Securities | 116,750,000 | — | — |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -151,606,000 | -30,000 | 79,000 |
| Tax Withholding For Share Based Compensation | 0 | 54,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 984,000 | 7,529,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 42,000,000 | 10,000,000 | 15,000,000 |
| Repayment Of Long Term Debt | 22,000,000 | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 267,269,000 | 253,196,000 | 21,848,000 |
| Change In Cash | -15,904,000 | 174,037,000 | -42,438,000 |
| Cash At End Of Period | 257,837,000 | 273,741,000 | 99,704,000 |
| Income Taxes Paid | 0 | — | — |
| Interest Paid | 5,338,000 | 2,224,000 | 534,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -2.06 | -1.54 | -2.44 |
| Price To Earnings Ratio | -6.5 | -4.5195 | -1.5 |
| Earnings Growth Rate | 33.7662 | -36.8852 | 32.6087 |
| Price Earnings To Growth Ratio | -0.1925 | 0.1225 | -0.046 |
| Book Value Per Share | 3.7203 | 3.4267 | 1.9954 |
| Price To Book Ratio | 3.5992 | 2.0311 | 1.8342 |
| Ebitda | — | — | — |
| Enterprise Value | 978,838,671.12 | 238,522,026.32 | 57,741,157.2 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.1221 | 0.0905 | 0.1808 |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | -0.553 | -0.4501 | -1.2252 |
| One Year Beta | 1.6613 | 1.9467 | 2.0597 |
| Three Year Beta | 1.8132 | 1.5862 | 1.7277 |
| Five Year Beta | 1.7336 | 1.5519 | 1.5199 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Roberts Brandi | Chief Financial Officer | 2026-09-25 | 3,377 | D | 394,528 |
| Sullivan Mark | Chief Legal Officer | 2026-09-25 | 14,051 | D | 494,228 |
| Wiley Matthew T. | Chief Commercial Officer | 2026-09-25 | 3,097 | D | 359,036 |
| Barrow Robert | Director, Chief Executive Officer | 2026-09-25 | 31,550 | D | 2,213,090 |
| Karlin Daniel | Director, Chief Medical Officer | 2026-09-25 | 10,853 | D | 792,846 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MassMutual Private Wealth & Trust, FSB | 2026-09-30 | 17,051 | 448 | 38.0603 |
| Versant Capital Management, Inc | 2026-09-30 | 3,425 | 90 | 38.0556 |
| ENVESTNET ASSET MANAGEMENT INC | 2026-06-30 | 782,087 | 16,626 | 47.04 |
| STATE STREET CORP | 2026-06-30 | 144,195,946 | 3,065,390 | 47.04 |
| Premier Financial Group | 2026-06-30 | 9,079 | 193 | 47.0415 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Science & Technology Fund Shares | USSCX | 700 | 30,464 | 0.002 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 14,458 | 629,212.16 | 0.0228 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 62,307 | 2,711,600.64 | 0.1821 |
| Advisors' Inner Circle Fund III | 2026-07-31 | I Shares | KCXIX | 610 | 26,547.2 | 0.0073 |
| VANGUARD EXPLORER FUND | 2026-07-31 | Admiral Shares | VEXRX | 511,828 | 22,274,754.56 | 0.1007 |